Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
12
12 articles ont été cités au moins 12fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
710
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
53
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
14
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire Henri-Mondor
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial
2023ArticleAlcohol and Alcoholism
Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines
2022ArticleLiver International
Occurrence and severity of cocaine-induced hallucinations: Two distinct phenotypes with shared clinical factors but specific genetic risk factors
2022ArticleDrug and Alcohol Dependence
Childhood trauma and the severity of past suicide attempts in outpatients with cocaine use disorders
2021ArticleSubstance Abuse
Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes
2004ArticleJournal of Hepatology
Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection
2003ArticleJournal of Hepatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HM SITE HENRI MONDOR
51 AV MAL DE LATTRE DE TASSIGNY, 94010 CRETEIL CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Liver international : official journal of the International Association for the Study of the Liver · 2017
AbstractBackground & AimsThe reliability of transient elastography (TE) to assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We aimed to validate the diagnostic utility of TE for liver fibrosis in patients with excessive alcohol consumption and evaluate whether Fibrotest® adds diagnostic value relative to or in combination with TE.MethodsWe conducted a multicentre prospective study on a total of 217 heavy drinkers with high serum aminotransferase levels. Patients underwent liver biopsy, TE, Fibrotest®, PGAA, APRI, FIB‐4 and FORNS. The overall diagnostic performance was evaluated by the area under the receiver operating characteristic (AUROC) curves and Obuchowski measures.ResultsTE values correlated with fibrosis stage (r=.73; P<.0001) and steatosis stage (r=.19; P<.01). Patients with alcoholic hepatitis had higher TE values than those without alcoholic hepatitis (P<.0001). In an multivariate analysis, fibrosis stage and the presence of alcoholic hepatitis were the only parameters that correlated with liver stiffness. For the diagnosis of advanced fibrosis (F≥3), the AUROC curves were 0.90, 0.85, 0.83, 0.91 and 0.90 for TE, Fibrotest®, PGAA and associations TE‐Fibrotest®, TE‐PGAA respectively. For the diagnosis of cirrhosis, the AUROC curves were 0.93, 0.88, 0.89, 0.94 and 0.95 respectively. The Obuchowski measures for the diagnosis of fibrosis were 0.94, 0.92, 0.91, 0.95 and 0.94 respectively. The performance of TE was not significantly different than those of Fibrotest®, PGAA and combinations TE‐Fibrotest®, TE‐PGAA.ConclusionsTE has excellent diagnostic value for liver fibrosis in alcoholic liver disease. The combined use of TE‐Fibrotest® or TE‐PGAA does not improve the performance of TE.
Journal of addiction medicine · 2018
Objectives: Since little is currently known about predictors of response to direct-acting antiviral agents (DAAs) in people who inject drugs, we undertook an analysis of patients attending a hepatitis clinic with addiction services (outpatient clinics and inpatient services) to examine the outcomes associated with the treatment of difficult-to-manage patients with substance use. Our experience was based on integrated care. Method: A retrospective analysis was undertaken of 50 patients with hepatitis C virus (HCV) and a history of addiction who received treatment with DAAs, according to European guidelines. These regimens were sofosbuvir/ledipasvir for 8 weeks (n = 3), sofosbuvir/ledipasvir ± ribavirin for 12 weeks (n = 19), sofosbuvir/daclatasvir for 12 weeks (n = 20), sofosbuvir/simeprevir (n = 1), or sofosbuvir/daclatasvir for 24 weeks (n = 7). Characteristics of patients who did versus did not achieve a sustained virologic response (SVR) 12 weeks after treatment were compared by univariate analysis. Results: Forty-two patients (84%) were male; mean age was 46.2 ± 7.3 years. Genotypes were 1 (n = 21), 2 (n = 4), 3 (n = 18), 4 (n = 6), or 6 (n = 1). Most patients were treatment-naïve (n = 38). Five patients had coinfection with human immunodeficiency virus (n = 4) or hepatitis B (n = 1), 28 (56%) had evidence of cirrhosis on FibroScan (>12.5 kPa), and 34 (68%) were receiving opioid substitution therapy. Psychiatric disease, illicit drug use, unemployment, and homelessness/precarious housing were common. Forty-five patients (90%) achieved SVR, 2 were lost to follow-up, and 3 had treatment relapse. Conclusions: SVR was not significantly associated with sociodemographic or virological characteristics, treatment, social environment, alcohol/drug use, and adherence. Although adherence was slightly worse than in “usual” patients, it did not affect the SVR rate. In these difficult-to-manage patients with HCV and substance use disorder, the real-world SVR rate (90%) was similar to that in nonaddicted populations.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Liver international : official journal of the International Association for the Study of the Liver · 2022 · Journal Article
Louvet A, Trabut JB, Moreno C, Moirand R, et al.
Journal of addiction medicine · 2018 · Journal Article
Trabut JB, Barrault C, Charlot H, Carmona D, et al.
Liver international : official journal of the International Association for the Study of the Liver · 2017 · Journal Article
Voican CS, Louvet A, Trabut JB, Njiké-Nakseu M, et al.
Presse medicale (Paris, France : 1983) · 2014 · English Abstract
Trabut JB, Thépot V, Terris B, Sogni P, et al.
European journal of gastroenterology & hepatology · 2009 · Case Reports
Quioc JJ, Trabut JB, Drouhin F, Malbrunot C, et al.
Human molecular genetics · 2006 · Journal Article
Rey RA, Venara M, Coutant R, Trabut JB, et al.
Alcohol and alcoholism (Oxford, Oxfordshire) · 2023 · Randomized Controlled Trial
Airagnes G, Valter R, Ducoutumany G, Vansteene C, et al.
Drug and alcohol dependence · 2022 · Journal Article
Zerdazi EH, Curis E, Karsinti E, Icick R, et al.
✨ Profil synthétique
IA · 19/05/2026Le Dr Jean-Baptiste Trabut est un rhumatologue hospitalier à Créteil Cedex. Ses recherches se concentrent principalement sur les maladies du foie, notamment le diagnostic et le traitement, ainsi que les effets de la consommation d'alcool sur la santé. Il a publié 53 travaux de recherche et possède un h-index de 12.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.